Anti-obesity agent and use thereof

An obesity and resistance technology, applied in the field of anti-obesity drugs and obesity treatment, can solve the problem of not inhibiting NPY

Inactive Publication Date: 2009-08-05
NAGOYA UNIVERSITY
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] As the main anti-obesity drugs currently clinically used, there are brain norepinephrine reabsorption inhibitor mazindol, brain norepinephrine / serotonin reabsorption inhibitor sibutramine, cannabinoid receptor Rimonabant, a selective antagonist of body 1, etc., neither drug has the effect of inhibiting NPY or enhancing POMC
On the other hand, it has been revealed that ciliary neurotrophic factor (CNTF) exhibits anti-obesity effects through the same signal transduction system as leptin, and its clinical application is currently being developed. Antibodies become a problem (Non-Patent Document 6)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-obesity agent and use thereof
  • Anti-obesity agent and use thereof
  • Anti-obesity agent and use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0045] The first aspect of the present invention relates to anti-obesity agents. The anti-obesity drug of the present invention (hereinafter also referred to as "drug of the present invention") contains GABA B A receptor agonist or a pharmacologically acceptable salt thereof is used as an active ingredient. That is, can be used in the present invention for GABA B Agonists of receptors. as GABA B Examples of receptor agonists include baclofen (baclofen), 3-aminopropyl (methyl) phosphinic acid (3-aminopropyl-(methyl) phosphinic acid (SKF97541)), 4-amino-3- (5-chloro-2-thienyl) butanoic acid (4-amino-3-(5-chloro-2-thienyl)-butanoic acid), 3-aminopropylphosphonic acid (3-aminopropylphosphonic acid), etc. GABA B A preferable example of the receptor agonist is baclofen. That is, a preferred embodiment of the present invention provides an anti-obesity drug comprising baclofen or a pharmacologically acceptable salt thereof as an active ingredient. Baclofen (chemical name: (RS)-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

Disclosed is a novel anti-obesity agent. Also disclosed is a therapeutic method using the anti-obesity agent. The anti-obesity agent comprises a GABAB receptor agonist or a pharmacologically acceptable salt thereof as an active ingredient.

Description

technical field [0001] The present invention relates to an anti-obesity drug, a treatment method for obesity and the like. Background technique [0002] In 1994, the pathogenic gene of the ob / ob mouse, a model animal of obesity and diabetes, was identified, thus showing that leptin deficiency is the cause of obesity and diabetes (Non-Patent Document 1). Leptin secreted from adipocytes acts on the arcuate nucleus of the hypothalamus as the primary center of feeding regulation, suppresses the expression of the hyperphagia peptide neuropeptide Y (NPY) expressed in the arcuate nucleus, and enhances α-MSH as an inhibitory peptide of feeding Expression of precursor proopiomelanocortin (POMC), thereby regulating energy balance in a negative direction (Non-Patent Documents 2, 3). However, the blood leptin concentration is generally high in obese persons, and sufficient anti-obesity effects have not been observed by administering leptin to obese persons (Non-Patent Documents 4 and 5...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/00A61P3/04A61K31/197A61P43/00
Inventor 有马宽佐藤郁子大矶裕
Owner NAGOYA UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap